Digital therapeutics are not interchangeable with wellbeing applications. A product described as an intervention must be analyzed for the specific claimed outcome, intervention mechanism, treatment population and clinical supervision model. Commercial adoption additionally depends on how a user arrives at the platform, who pays and what information the platform collects.
Digital therapeutics are not interchangeable with wellbeing applications. A product described as an intervention must be analyzed for the specific claimed outcome, intervention mechanism, treatment population and clinical supervision model. Commercial adoption additionally depends on how a user arrives at the platform, who pays and what information the platform collects.
This page concerns research and strategic decision support for Digital therapeutics founders, payers and health systems. The starting point is a defined decision—such as technology selection, partnership diligence, investment screening or a product roadmap—not an assumption that a published demonstration applies to every commercial setting.
Evidence should be identified by date, source, applicable product configuration and test boundary. Supplier claims, patents, industry standards, peer-reviewed results and official permissions answer different questions. A reliable brief records disagreements among them and identifies the information that remains unavailable, rather than treating missing information as evidence of suitability.
Compare therapeutic claims with the proposed intervention, control group and measurable endpoint. Distinguish convenience, engagement and satisfaction metrics from health outcomes, and examine how participant dropout affects reported results.
Specify data sources, exclusions and decision criteria before treating a technical claim as a commercial conclusion.
Document onboarding, adherence patterns, clinician involvement, accessibility and exclusion criteria. High usage may signal usability but cannot by itself establish a clinically meaningful effect or lasting behavioural change.
Specify data sources, exclusions and decision criteria before treating a technical claim as a commercial conclusion.
Map reimbursement assumptions, privacy duties, integration with payer or provider systems and rights in clinical content. An attractive subscription forecast does not settle whether a payer will recognize the product or authorize the data flow.
Specify data sources, exclusions and decision criteria before treating a technical claim as a commercial conclusion.
The following are illustrative research products, not claims of work previously performed for a named client. Final deliverables depend on the source material supplied, jurisdiction, technical configuration and commercial objective.
Create a versioned source register, compare suppliers or methods under explicit inclusion criteria, and identify where a critical assumption lacks independent support. The output should tell the decision maker what is known, what is inferred and what needs further testing.
For digital therapeutics and health platforms, this output should be tailored to the relevant product, use case and the supporting evidence identified in the preceding research dimensions.
Translate the research into alternatives: baseline, pilot and phased deployment. Identify dependencies such as data availability, specialist review, commercial rights and implementation costs. Highlight sensitivity to assumptions rather than presenting a single guaranteed outcome.
For digital therapeutics and health platforms, this output should be tailored to the relevant product, use case and the supporting evidence identified in the preceding research dimensions.
Prepare a practical issue register for partners and internal teams. Associate each open question with the evidence needed to resolve it, responsible decision owner and potential effect on timing, commercial terms or technical suitability.
For digital therapeutics and health platforms, this output should be tailored to the relevant product, use case and the supporting evidence identified in the preceding research dimensions.
A health platform seeks to move from corporate wellness sales to a clinician-referred therapeutic product. A research assignment could compare the existing marketing claims with trial evidence and proposed outcomes, identify gaps between enterprise buyer needs and clinical procurement expectations, and prepare separate commercial pathway scenarios for each intended market.
Before any decision memo is finalized, test a negative scenario: what if the best-looking solution performs materially worse in another location, changes configuration, lacks the required data rights, or cannot meet the operating environment? Counter-evidence may change the ranking or justify a smaller pilot.
Choose metrics aligned to the actual buyer decision. Each measure should have a unit, method of measurement, boundary, observation period and reason it may fail to reflect real deployment:
Report missing measurements explicitly. Differences in geography, hardware, operating time, user population and source definitions can invalidate simple comparisons. If normalization cannot be justified, present findings side by side with their limitations instead of manufacturing a composite score.
Record the decision owner, proposed use, product boundary, countries implicated and available technical evidence. Agree on exclusion criteria before selecting the preferred supplier or method.
Review primary institutional materials, peer-reviewed findings, patents and supplier records. Capture source dates, tested versions, contradictory results and uncertainty in a source ledger.
Summarize defensible options with implementation dependencies, open questions, and the responsible parties for independent professional or technical verification.
For this sector, the source-review plan should explicitly revisit therapeutic claim versus wellness claim, clinical outcomes and engagement measurement, and reimbursement, privacy and distribution model. Any material change in product configuration or commercial use may require the conclusions to be re-tested.
A health-app comparison cannot establish treatment efficacy, reimbursement eligibility or device classification.
Outputs are research and commercial-strategy inputs. They do not independently establish safety, regulatory approval, clinical efficacy, legal compliance, financial return or permission to operate. Jurisdiction-specific regulated professional opinions, certifications, testing and authorizations must be obtained from appropriately qualified parties when applicable.
The main institutional starting point is FDA digital-health guidance. This reference provides research context, not a certification or endorsement of this website. Publication dates and current applicability should be checked at the point of engagement.
Connected technology, strategy or research context already available on this website.
Connected technology, strategy or research context already available on this website.
Explore all industry research · Consulting services · Contact and project enquiries
Start with the intended buyer decision, existing product description and any source records relevant to therapeutic claim versus wellness claim. Include dated technical results and known counterexamples; missing records can be tracked during scoping.
A health-app comparison cannot establish treatment efficacy, reimbursement eligibility or device classification. A research brief identifies open requirements and may coordinate questions for independent qualified reviewers; it is not a substitute for their determination.
A focused comparison may combine digital intervention evidence register, commercial pathway scenarios and an evidence gap register. It should contain a recommendation conditional on test boundaries rather than an unconditional adoption or investment instruction.
Share the target decision, sector, key jurisdictions, available evidence, constraints and required deliverables. Use the enquiry form for structured requests or email for documents that need attachments. Engagement scope and any regulated professional requirements are confirmed individually.